Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma (NCT06580223) | Clinical Trial Compass
Not Yet RecruitingPhase 3
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
China530 participantsStarted 2025-09-01
Plain-language summary
The aim of this study is to evaluate the efficacy and safety of aspirin and rivaroxaban in thromboprophylaxis in Chinese MM patients at high risk for MM-associated VTE.
Who can participate
Age range
18 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Newly diagnosed multiple myeloma (according to Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision))
. High risk of VTE (according to Expert consensus on the prevention and treatment of multiple myeloma related venous thromboembolism in China (2022))
. Life expectancy exceeding 12 months
. Gender: not specified, Age: 18-90 years
. Serum HIV antigen or antibody negative
. HCV antibody negative, or HCV antibody positive with HCV RNA negative
. Echocardiogram shows a left ventricular ejection fraction of ≥50%
. Ability to sign an informed consent form
Exclusion criteria
. Pregnant women or women who are breastfeeding
. Active gastrointestinal ulceration
. Active bleeding
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of VTE within 6 months
Timeframe: 6 months
Trial details
NCT IDNCT06580223
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
. When initiating treatment, platelet count below 50 G/L, or with PT prolonged by more than 3 seconds, and APTT prolonged by more than 10 seconds.
. Abnormal liver function (ALT or AST greater than 3 times the upper limit of normal, or total bilirubin greater than 2 times the upper limit of normal)
. Abnormal renal function (creatinine clearance \< 30 mL/min)
. Unable to cooperate in completing the clinical trial